MELBOURNE, Australia, 13 October 2022 – Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, has opened today a brand-new state-of-the-art facility to strengthen the company’s research and manufacturing capabilities, as well as support local innovation. Cartherics invested AU$4M in the newly designed and built facility, which includes PC2 and dedicated […]
Melbourne, Australia, 06 October 2022 – Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it has been granted US patent 11,400,145, entitled “Genetically modified cells and uses thereof”.
This patent provides a proprietary position for multiple development candidates in Cartherics’ pipeline. Specifically, this patent covers Cartherics’ chimeric […]
By Leigh Dayton, 16 June 2022
Cartherics is delighted to announce that Non-Executive Director Bryan Williams is one of the top 1000 scientists worldwide in the field of Genetics and Molecular Biology, according to Research.com, a prominent academic platform for scientists.
In the recently released edition its […]
By Leigh Dayton 9 June 2022
It’s official. As of this month, ovarian cancer campaigner Heather Hawkins takes up her role as an Advisory Board Member for Cartherics.
“It’s a privilege and an honour to be part of the Board,” she says. “And I’m looking forward to assisting […]
Chief Development Officer, Dr Nicholas Boyd
Cell therapies have the potential to not only be life-saving but curative for a host of diseases. However, inherent limitations in autologous based CAR-T therapy face major roadblocks for mass adoption and therapeutic effects in solid tumour indications.
On Friday 28 January at 7:30 am AEDT Nicholas will discuss the design, […]
By Leigh Dayton, 17 January 2022
Cellular immunotherapy is revolutionizing cancer treatment, and off-the-shelf or allogeneic, treatments are beginning to replace technologies developed individually for each patient.
This is good news because the potential of allogeneic therapies is great. They promise to significantly save time and cut costs compared […]
By Leigh Dayton, 4 January 2022
When Cartherics Biomedical Honours student Elizabeth (Liz) Bakaniozos opened an e-mail this month from the Director and CEO of Monash University’s Hudson Institute of Medical Research she was “really surprised and grateful”.
And rightly so. Elizabeth Hartland wrote to advise and congratulate Liz on winning the Hudson Institute Lois Salamonsen Honours […]
By Leigh Dayton, 6 December 2021
When eight Cartherics women first teamed-up to walk or run 4km every day in November and raise funds to support women living with ovarian cancer, they set what they believed were achievable goals. The newly minted CARTeam would collectively move 120 km and raise $500.
They sorely misjudged their efforts. Despite […]
By Leigh Dayton 22 November 2021
It was a challenge that had to be met. “This November, walk or run 4km every day and raise funds to support women living with ovarian cancer,” proposed Ovarian Cancer Australia (OCA), a not-for-profit organisation which supports women […]
‘Off-the-Shelf’ Immunotherapy: Manufacture of CD8+ T Cells Derived from Hematopoietic Stem Cells
Cellular immunotherapy is revolutionizing cancer treatment. However, treatments created from each patient’s cells are complex, costly, and limited by the number and quality of killer T cells that can be isolated from and expanded for re-infusion into each patient.
In this […]
Cartherics’ mission is the development of novel, “off-the-shelf” (allogeneic) immune cell therapy products for the treatment of cancer.
Stay informed about our latest news and developments
© Copyright 2022 | Cartherics Pty ltd
